Why cost per milligram fails in the semaglutide market
The most common way to compare GLP-1 analogue prices produces the wrong ranking. The unit that supports commercial decisions is not the milligram — it is the treatment week.
BY Life Science Intelligence · PUBLISHED August 08, 2026 · 5 min read
UPDATED September 17, 2026
EXECUTIVE SUMMARY
- Cost per milligram is an input-cost metric applied to a treatment with mandatory dose escalation.
- The commercial decision unit is the treatment week: total presentation mass divided by the indicated weekly dose.
- The wrong metric makes titration presentations look expensive, maintenance presentations look cheap and molecule comparisons unreliable.
- Comparability requires a single price reference and the declared label dose, not a generic target dose applied across all SKUs.
- Normalized by week, Brazil’s semaglutide market converges; the relevant signal is not parity, but the SKU that moves outside the range.
The error is the unit, not the calculation
Cost per milligram is a metric borrowed from inputs. It works when a product is consumed in bulk, continuously and proportionally to dose. Semaglutide is not like that.
Treatment follows a mandatory clinical dose escalation: it starts at 0.25 mg weekly, rises to 0.5 mg, then 1.0 mg, and only then reaches the maintenance dose. Each commercial presentation is designed to cover a specific segment of that curve: some cover four weeks of initial titration, others cover four weeks of high-dose maintenance.
This means that two presentations with the same cost per milligram can cover radically different treatment periods. And two presentations with very different cost per milligram can cost almost the same per week of therapy.
The patient does not buy milligrams. The patient buys weeks.
What the wrong metric distorts
Three recurring distortions appear:
Titration presentations look expensive. They concentrate less drug mass per pen, but carry the same device, packaging and cold-chain cost. Per milligram, they look disadvantaged. Per week, they are in line.
Maintenance presentations look cheap. They spread the fixed device cost over more mass. The apparent gain per milligram is largely a device-scale effect, not a lower treatment price.
Molecule comparisons become unworkable. Semaglutide, tirzepatide and liraglutide operate across dose ranges with no direct relationship to one another. Comparing tirzepatide at 15 mg with liraglutide at 3 mg by milligram is not a difficult comparison: it is a meaningless one.
The correct unit
Two conditions are required for the result to be comparable:
- One price reference. Mixing manufacturer price, consumer maximum price and observed market price in the same frame invalidates the exercise. For a regulatory reading, use the consumer maximum price with the tax rate of the market being analyzed.
- Declared dose, not theoretical dose. The weekly dose must be the one indicated for the presentation according to the label, not a generic maintenance target applied indistinctly to every SKU.
What appears when the unit changes
When this normalization is applied to the main semaglutide presentations available in Brazil, the result is a narrow convergence in weekly cost across SKUs, including presentations that appeared to show double-digit percentage differences when measured by milligram.
Convergence is not a coincidence. It is what one would expect in a market where the regulated ceiling and manufacturers’ portfolio architecture operate over the same dose curve. Parity is the normal behavior.
What matters, therefore, is not parity. It is the deviation: the SKU that materially moves away from the range. A relevant deviation may indicate a registration error, a deliberate entry strategy, a channel difference or a line repositioning — and each hypothesis leads to a different commercial decision.
Identifying the deviation requires the right unit. With cost per milligram, the deviation dissolves into presentation-level noise.
Practical consequence
| Situation | Correct question |
|---|---|
| Pricing definition | What is the weekly-cost range of the competitive benchmark, not the milligram table? |
| Negotiation with a distributor or payer | What is the treatment cost? The per-milligram argument can be easily dismantled by the other side. |
| Assessment of a generic or similar entrant | What weekly treatment cost can the entrant reach? |
What remains open
Is the observed convergence stable over time, or is it only a snapshot before new registrations enter the market? With the synthetic pipeline advancing, the parity range may break downward, and the speed of that break is currently the most relevant variable in Brazil’s GLP-1 market.
It is the kind of movement that only appears in a time series.
GLP1 RADAR tracks price, regulation and competitive movement in Brazil’s GLP-1 market through interpreted biweekly analysis.
METHOD
Calculation based on the current CMED table, using consumer maximum price with an 18% tax rate, and injectable semaglutide presentations with active registration. Weekly doses follow each presentation’s label. Regulated ceiling price and observed market price are distinct measures and were not mixed; the difference between them is tracked separately.
Lisa Radar
The Brazilian GLP-1 market, read every two weeks.